| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| ln Vitro |
The most prevalent cancer types' cells show antiproliferative activity when exposed to antitumor agent-81 (0–20 µM; 72 h)[1]. In HCT-116 cells, antitumor agent-81 (1, 2, 5 µM; 24 h) impairs HR (homologous recombination)-mediated DSB repair[1]. In HCT-116 cells, antitumor agent-81 tethers the relationship between P62 and RNF168[1]. In HCT-116 cells, antitumor agent-81 inhibits RNF168's catalytic activity as well as RNF168 E3 ligase activity[1].
|
|---|---|
| ln Vivo |
Tumor volumes are suppressed in mice by antitumor agent-81 (5, 10 mg/kg; ip; once every three days for 22 days) in a dose-dependent manner[1]. 1.19 Antitumor agent-81 pharmacokinetic parameters in female BALB/c nude mice[1]. IP (5 mg/kg) 16.17 26.10 215.69 19647.83 IP (10 mg/kg) 31.00 39.87 408.18 16554.30 IP (20 mg/kg) 22.10 52.23 1003.58 14669.81 Dose T1/2 (h) Cmax (ng/mL) AUC0-t (h㻿ng/mL) CL ((mL/h)/kg)
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells Tested Concentrations: 0 -20 µM Incubation Duration: 72 h Experimental Results: Inhibited A549, HCT-116, A375, HeLa, HepG2, MCF-7, MDA-MB-231, MGC-803, U2OS and MCF-10A cells, with IC50 values of 1.18, 0.36, 1.93, 2.48, 19.61, 2.79, 1.17, 1.88, 3.64 and 6.98, respectively. Cell Cycle Analysis[1] Cell Types: HCT-116 cells Tested Concentrations: 1, 2, 5 µM Incubation Duration: 24 h Experimental Results: Induced a G2/M arrest but no significant accumulation of sub-G1 phase. Compromised both HR(homologous recombination)- and NHEJ (non-homologous end joining)- mediated DSB repair in a dose-dependent manner, but HR was the more severely impacted process . |
| Animal Protocol |
Animal/Disease Models: Female BALB/c nude mice (xenograft tumor model)[1].
Doses: 5, 10 mg/kg Route of Administration: intraperitoneal (ip) injection; single every 3 days for 22 days Experimental Results: Suppressed tumor growth by promoting apoptosis in xenografted tumorigenesis. Animal/Disease Models: Female BALB/c nude mice[1]. Doses: 5, 10, 20 mg/kg Route of Administration: intraperitoneal (ip) injection; single Experimental Results: demonstrated plasma concentration peaked 1 h after administration. demonstrated a relatively high maximum concentration (Cmax= 52.23 ng/mL) and exposure (AUC0-t= 1003.58 h·ng/mL) at a dose of 20 mg/kg. |
| References |
| Molecular Formula |
C19H19N7O3
|
|---|---|
| Molecular Weight |
393.399262666702
|
| Exact Mass |
393.154
|
| CAS # |
2765180-17-2
|
| PubChem CID |
163214076
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
1.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
530
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1OC)OC)N2C=C(N=N2)C3=CC4=C(C=C3)N=C(N=C4N)N
|
| InChi Key |
SWULRQWLALOGFO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19N7O3/c1-27-15-7-11(8-16(28-2)17(15)29-3)26-9-14(24-25-26)10-4-5-13-12(6-10)18(20)23-19(21)22-13/h4-9H,1-3H3,(H4,20,21,22,23)
|
| Chemical Name |
6-[1-(3,4,5-trimethoxyphenyl)triazol-4-yl]quinazoline-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 60 mg/mL (~152.5 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.4 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (24.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.4 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (24.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.4 mg/mL (6.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (24.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5419 mL | 12.7097 mL | 25.4194 mL | |
| 5 mM | 0.5084 mL | 2.5419 mL | 5.0839 mL | |
| 10 mM | 0.2542 mL | 1.2710 mL | 2.5419 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
